Moderna (NASDAQ:MRNA) Given New $111.00 Price Target at Barclays

Moderna (NASDAQ:MRNA - Free Report) had its price target reduced by Barclays from $125.00 to $111.00 in a research report report published on Friday,Benzinga reports. They currently have an overweight rating on the stock.

MRNA has been the topic of several other research reports. Leerink Partners reduced their target price on shares of Moderna from $60.00 to $48.00 and set an "underperform" rating on the stock in a report on Tuesday, September 17th. Piper Sandler cut their target price on Moderna from $157.00 to $115.00 and set an "overweight" rating on the stock in a research report on Friday, September 13th. HSBC raised shares of Moderna from a "reduce" rating to a "hold" rating and set a $82.00 price target for the company in a research report on Wednesday, August 28th. Jefferies Financial Group dropped their price target on Moderna from $65.00 to $55.00 and set a "hold" rating on the stock in a research note on Tuesday, October 15th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Moderna in a research note on Friday. Two analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Moderna presently has a consensus rating of "Hold" and a consensus price target of $93.18.

Moderna Stock Down 6.9 %

Shares of NASDAQ MRNA traded down $3.45 during midday trading on Friday, hitting $46.83. The company's stock had a trading volume of 13,561,538 shares, compared to its average volume of 4,882,079. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92. The firm has a market capitalization of $18.00 billion, a price-to-earnings ratio of -3.04 and a beta of 1.69. The business's fifty day simple moving average is $61.85 and its two-hundred day simple moving average is $99.16. Moderna has a 1 year low of $46.57 and a 1 year high of $170.47.

Moderna (NASDAQ:MRNA - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The firm had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. During the same period last year, the business posted ($1.39) earnings per share. Moderna's revenue was up 3.8% compared to the same quarter last year. On average, equities analysts predict that Moderna will post -9.89 EPS for the current year.

Insider Buying and Selling

In other Moderna news, CFO James M. Mock sold 715 shares of the company's stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now owns 9,505 shares in the company, valued at approximately $571,440.60. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO James M. Mock sold 1,321 shares of the firm's stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares of the company's stock, valued at approximately $682,754. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO James M. Mock sold 715 shares of the company's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the transaction, the chief financial officer now directly owns 9,505 shares of the company's stock, valued at $571,440.60. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,184 shares of company stock worth $238,531 in the last three months. 15.70% of the stock is currently owned by insiders.

Institutional Trading of Moderna

Institutional investors and hedge funds have recently modified their holdings of the company. Ashton Thomas Private Wealth LLC bought a new position in shares of Moderna during the 2nd quarter worth about $26,000. Cedar Wealth Management LLC raised its holdings in shares of Moderna by 45.0% in the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company's stock worth $31,000 after buying an additional 90 shares in the last quarter. Family Firm Inc. bought a new position in shares of Moderna during the 2nd quarter worth approximately $33,000. Bank & Trust Co acquired a new stake in Moderna in the 2nd quarter valued at $36,000. Finally, Hanseatic Management Services Inc. bought a new stake in Moderna in the second quarter valued at $48,000. 75.33% of the stock is currently owned by institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.